"Prototype Drug Uses Novel Mechanism To Treat Lung Cancers"
Cells are constantly turning proteins on and off via molecular switches-phosphate molecules-that have become common drug targets. Researchers collaborated to screen a series of drug-like molecules for their ability to reactivate PP2A in lung cancer cells and prevent lung cancer tumors in mice. The prototype drug molecules were created from FDA-approved medications by Michael Ohlmeyer, PhD, an associate professor of pharmacological sciences at the Icahn School of Medicine at Mount Sinai.
- Michael Ohlmeyer, PhD, Associate Professor of Pharmacological Sciences at the Icahn School of Medicine at Mount Sinai
Learn more
Study Reveals New Insights Into Immune System Role in Lung Cancer Risk
Feb 22, 2024 View All Press Releases
Researchers Discover Why One Type of Chemotherapy Works Best in Bladder Cancer
Jan 26, 2024 View All Press ReleasesMount Sinai’s Staten Island Cancer Center Moves to New Site
Nov 09, 2023 View All Press Releases
Scientists Create Most Powerful, Accurate Tool Yet to Research Deadliest Blood Cancer
Apr 18, 2023 View All Press Releases